Federal Circuit Affirms District Court Decision Holding Asserted Software Claims Invalid as Directed to Patent Ineligible Subject Matter

Oct 28, 2016

Reading Time : 1 min

The Federal Circuit affirmed the district court’s decision and found that the claims were directed to a patent-ineligible abstract idea: the concept of analyzing records of human activity to detect suspicious behavior.  The court agreed that the claimed method is nothing more than a combination of several abstract ideas previously found ineligible under § 101, including collecting information, analyzing information and presenting the results of an abstract process.

The court contrasted the claims of the ’500 patent with those at issue in McRO, Inc. v. Bandai Namco Games America, Inc. In McRO, the court found McRO’s claims patent-eligible because they were directed to a specific asserted improvement in computer animation that used rules to accurately synchronize animated lips for on screen characters. This was previously done by animators; thus, the rules were critical to the implementation of the process on a computer. In contrast, the claims in the ’500 patent did not use rules to improve an existing technological process, but rather merely implemented an old practice in a new environment

Turning to step two of the patent-eligibility inquiry, the court found that the claims fail to add something more or transform the claimed abstract idea of collecting information and analyzing into a patent-eligible application of the abstract idea. The ’500 patent claims merely use generic computer elements such as microprocessors and user interfaces, which are not enough to transform an otherwise abstract idea into patent-eligible subject matter. Moreover, the claims do not propose a solution or overcome a problem specifically arising in the realm of computer technology.

The court also rejected FairWarning’s argument that the ’500 patent does not pre-empt the field of Health Insurance Portability and Accountability Act (HIPAA) regulation compliance. The court held that the absence of complete field pre-emption does not demonstrate patent eligibility, and the fact that the ’500 patent’s claims might not pre-empt the entire field of HIPAA compliance does not make them any less abstract.

FairWarning IP, LLC v. Iatrict Systems, Inc., Case No. 2015-1985 (Fed. Cir. Oct. 11, 2016).

Share This Insight

Previous Entries

IP Newsflash

June 6, 2025

In a precedential opinion, the Federal Circuit definitively held that the Patent Trial and Appeal Board has jurisdiction over IPRs that concern expired patents.

...

Read More

IP Newsflash

June 6, 2025

In a patent infringement litigation in the U.S. District Court for the Eastern District of Texas, Judge Rodney Gilstrap denied a joint motion to stay the litigation pending resolution of inter partes review when it was uncertain that all defendants would be bound by the statutory estoppel provision of 35 U.S.C. § 315(e).

...

Read More

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged claim construction issues or the number, length or scope differences of the challenged claims.

...

Read More

IP Newsflash

May 9, 2025

The USPTO Director vacated the board’s decision to institute inter partes review based on an erroneous application of the Fintiv factors. Specifically, the Director found that the board placed too much emphasis on Petitioner’s Sotera stipulation, and not enough emphasis on the investment in the parallel litigation. Weighing the factors as a whole, the Director determined that institution should be denied.

...

Read More

IP Newsflash

May 9, 2025

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.